Connect
MJA
MJA

Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers to prevent end-stage kidney disease in patients who do not have diabetes

Giovanni FM Strippoli and Craig C Jonathan
Med J Aust 2004; 181 (8): 450-451.
Published online: 18 October 2004

In patients without diabetes, but with impaired renal function and proteinuria, does combination treatment with the angiotensin-converting enzyme (ACE) inhibitor trandolapril and the angiotensin-receptor blocker (ARB) losartan prevent deterioration of renal function more effectively than treatment with either agent used alone?

  • Giovanni FM Strippoli1
  • Craig C Jonathan2

  • 1 Centre for Kidney Research, Cochrane Renal Group, NHMRC Centre of Clinical Research Excellence in Renal Medicine, The Children’s Hospital at Westmead, University of Sydney, Sydney, NSW.
  • 2 Centre for Kidney Research, NHMRC Centre of Clinical Research Excellence in Renal Medicine, Cochrane Renal Group, School of Public Health, University of Sydney, Australia, Sydney, NSW.

Correspondence: 

Competing interests:

None identified.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.